arrow
C

Chung-Pin Li

Taipei Veterans General Hospital
H指数:42
被引数:8,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to comment on “Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX”

对“在解释改良FOLFIRINOX最佳初始相对剂量强度时考虑5-氟尿嘧啶剂量强度的未测量影响”的评论回复

2026-05-220
OAAI
NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study

NALIRIFOX与脂质体伊立替康联合氟尿嘧啶/亚叶酸钙作为吉西他滨耐药胰腺腺癌的二线化疗:一项真实世界研究

2026-03-190
OA
SLOG versus Modified FOLFIRINOX as First-Line Treatment for Advanced Pancreatic Cancer: A Randomized Phase II Trial (TCOG T5217)

SLOG与改良FOLFIRINOX作为晚期胰腺癌一线治疗的比较:一项随机II期临床试验(TCOG T5217)

2026-01-110
PRE
Clinical impact of pharmacogenetic risk variants in a large chinese cohort

Wei, C.-Y.; Wen, M.-S.; Cheng, C.-K.; Sheen, Y.-J.; Yao, T.-C.; Lee, S.-L.; Wu, J.-Y.; Tsai, M.-F.; Li, L.-H.; Chen, C.; et al. 药物基因组学风险变异在一个大型中国人群中的临床影响。Nat. Commun. 2025, 16, 6344. [Google Scholar] [CrossRef]

2025-07-090
OAAI
Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis

胞外囊泡分析磷脂酰肌醇蛋白-1 mRNA和蛋白对胰腺癌诊断和预后的价值

2024-01-107
OAAI
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Napabucasin联合nab-紫杉醇联合吉西他滨与nab-紫杉醇联合吉西他滨在先前未治疗的转移性胰腺癌中的比较: 一项适应性多中心,随机,开放标签,3期,优越性试验

2023-04-019
OAAI